12/2018
FASN inhibition as a potential treatment for therapy of endocrine resistant breast cancer
San Antonio Breast Cancer Symposium
Read More
11/2018
Updated results from a prospective, randomized phase 2 study in patients with first relapse of high-grade astrocytoma using TVB-2640 in combination with Avastin versus Avastin alone
Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology
Read More
02/2017
Fatty Acid Synthase – Modern Tumor Cell Biology Insights into a Classical Oncology Target
Pharmacology and Therapeutics
Read More
12/2016
FASN inhibition and taxane treatment combine to enhance anti-tumor efficacy in diverse xenograft tumor models through disruption of tubulin palmitoylation and microtubule organization and FASN inhibition-mediated effects on oncogenic signaling and gene expression
EBioMedicine
Read More
09/2016
Mechanism and rationale for inhibition of FASN as a novel therapy for KRAS-mutant non-small cell lung cancer patients
Precison: Lung Cancer R&D Summit
Read More
08/2016
DeNovo Palmitate Synthesis Supports Oncogenic Signaling Through Diverse Mechanisms: Implications for FASN-Targeted Therapeutics
Journal of Cell Signaling
Read More
12/2015
Direct Inhibition of Cellular Fatty Acid Synthase Impairs Replication of Respiratory Synctial Virus and Other Respiratory Viruses
PLOS ONE
Read More
06/2015
First-in-Human Investigation of the Oral First-in-Class Fatty Acid Synthase (FASN) Inhibitor, TVB-2640
ASCO Annual Meeting
Read More
11/2014
Initial report of a first-in-human study of the first-in-class fatty acid synthase (FASN) inhibitor, TVB-2640
EORTC-NCI-AACR International Conference
Read More
11/2014
Mechanistic analysis of reversible FASN inhibition in preclinical tumor models identifies highly susceptible tumor types and enriches biomarker discovery for clinical applications
EORTC-NCI-AACR International Conference
Read More